- Anniversary/History
- Membership
- Publications
- Resources
- Education
- Events
- Outreach
- Careers
- About
- For Pain Patients and Professionals
Papers: 28 Sep 2019 - 4 Oct 2019
Human Studies, Pharmacology/Drug Development
PAIN TYPE:
Itch
2020 Jul
Br J Dermatol
183
1
Dupilumab, a human monoclonal antibody, blocks the shared receptor unit for interleukin-4 and interleukin-13. International phase II and III studies have evaluated the efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis (AD), but dupilumab effects in Japanese patients have not been reported.